Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Apr;33(4):434–436. doi: 10.1128/aac.33.4.434

Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.

V X Nguyen 1, D E Nix 1, S Gillikin 1, J J Schentag 1
PMCID: PMC172455  PMID: 2729939

Abstract

The effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline was studied. In a randomized crossover design, six healthy male volunteers received an infusion of 200 mg of doxycycline hyclate on two occasions separated by 7 days. On one occasion, subjects were given 30 ml of aluminum hydroxide orally four times a day for 4 days, beginning 2 days prior to doxycycline dosing. Blood and urine samples were collected up to 48 and 96 h after the infusion, respectively, and were analyzed by a microbial assay. Values for volume of distribution at steady state, nonrenal clearance, urine recovery, and urine pH were not statistically different among treatment groups. With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008). Area under the concentration-time curve for serum was decreased by 18 to 44%, with a 22 to 41% increase in renal clearance. Although the increase in nonrenal clearance ranged from 11 to 128%, the high variability led to a nonsignificant difference (P = 0.07). Concomitant oral antacid therapy may significantly enhance the clearance of intravenous doxycycline.

Full text

PDF
434

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALBERT A., REES C. W. Avidity of the tetracyclines for the cations of metals. Nature. 1956 Mar 3;177(4505):433–434. doi: 10.1038/177433a0. [DOI] [PubMed] [Google Scholar]
  2. Chin T. F., Lach J. L. Drug diffusion and bioavailability: tetracycline metallic chelation. Am J Hosp Pharm. 1975 Jun;32(6):625–629. [PubMed] [Google Scholar]
  3. Cunha B. A., Sibley C. M., Ristuccia A. M. Doxycycline. Ther Drug Monit. 1982;4(2):115–135. doi: 10.1097/00007691-198206000-00001. [DOI] [PubMed] [Google Scholar]
  4. Fourtillan J. B., Lefebvre M. A., Saux M. C., Becq-Giraudon B. Etude pharmacocinétique de la doxycycline chex l'homme par chromatographie liquide haute performance. Administration de doses uniques de 200 mg par voie intra-veineuse et par voie orale. Nouv Presse Med. 1980 Jan 10;9(21 Suppl):77–81. [PubMed] [Google Scholar]
  5. Gibaldi M., Grundhofer B., Levy G. Time course and dose dependence of antacid effect on urine pH. J Pharm Sci. 1975 Dec;64(12):2003–2004. doi: 10.1002/jps.2600641223. [DOI] [PubMed] [Google Scholar]
  6. Kaehny W. D., Hegg A. P., Alfrey A. C. Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med. 1977 Jun 16;296(24):1389–1390. doi: 10.1056/NEJM197706162962407. [DOI] [PubMed] [Google Scholar]
  7. Nelis H. J., De Leenheer A. P. Evidence for metabolic inertness of doxycycline. J Pharm Sci. 1981 Feb;70(2):226–228. doi: 10.1002/jps.2600700230. [DOI] [PubMed] [Google Scholar]
  8. Neuvonen P. J., Penttilä O. Effect of oral ferrous sulphate on the half-life of doxycycline in man. Eur J Clin Pharmacol. 1974 Aug 23;7(5):361–363. doi: 10.1007/BF00558207. [DOI] [PubMed] [Google Scholar]
  9. Pedersen P. V., Miller R. Pharmacokinetics of doxycycline reabsorption. J Pharm Sci. 1980 Feb;69(2):204–207. doi: 10.1002/jps.2600690224. [DOI] [PubMed] [Google Scholar]
  10. Swarz H. Metabolism of doxycycline and other tetracyclines. Med Chir Dig. 1976 May 8;5(6):323–325. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES